Published Date: 08 Mar 2023
Interventions to improve clinical practice increased the odds that people with type 2 diabetes and heart disease were prescribed the drugs recommended in our study by more than 100%.
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
Prostate cancer early detection system eliminates need for biopsy.
2.
Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.
3.
3D virtual staining technology enables non-invasive observation of cancer tissue
4.
Healthcare in the Mix in President Biden's Farewell Address
5.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
1.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
2.
Uncovering the Causes of Thrombocytosis: A Journey to Improved Health
3.
Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis
4.
Multiple Myeloma: Understanding the Basics
5.
Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation